TriangleNeratinib + Trastuzumab Deruxtecan (NCT05274048)
Neratinib + Trastuzumab Deruxtecan trial for HER2-Positive Advanced Gastro-Esophageal and GI Cancers (NCT05274048). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced gastro-esophageal or other gastrointestinal cancers that are HER2 positive, after earlier treatment.
The idea: combine neratinib, a daily pill, with trastuzumab deruxtecan, given by vein on day one of each 21 day cycle. Small groups of patients receive rising doses of neratinib.
This phase 1 study plans 18 patients and looks for the maximum tolerated dose and recommended phase 2 dose. At Fox Chase Cancer Center in Philadelphia, Namrata Vijayvergia leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.